XSHE
002581
Market cap314mUSD
Jul 10, Last price
3.30CNY
1D
2.17%
1Q
-55.35%
Jan 2017
-86.40%
IPO
-59.53%
Name
Shandong Sinobioway Biomedicine Co Ltd
Chart & Performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Shandong Sinobioway Biomedicine Co., Ltd., headquartered in Zibo, China, is a key producer and supplier of various chemical compounds, including trimethyl orthoformate, triethyl orthoformate, trimethyl orthoacetate, phosphorous acid, and ethyl formate. The company also manufactures general nerve growth factor and alfaron. Its pharmaceutical offerings further encompass NOBEX, which is a murine nerve growth factor delivered via injection; Anferon, a human recombinant interferon alpha 2b injection; and Jaferon, a human recombinant interferon alpha 2b formulated as a spray. Beyond these, the company provides a diverse portfolio of vaccines such as Healive, an inactivated vaccine for hepatitis A; Bilive, a combined vaccine targeting both hepatitis A and B; Panflu, designed for pandemic influenza; Anflu, a preservative-free influenza virus vaccine; and Panflu.1, specifically for Type A H1N1 influenza, among other related products. Established in 2000, its market extends internationally, with products being exported to roughly 20 nations and territories across Europe and the United States.
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2023‑00 | 2022‑12 | 2022‑00 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||||
Revenues | ||||||||||||
Cost of revenue | ||||||||||||
Unusual Expense (Income) | ||||||||||||
NOPBT | ||||||||||||
NOPBT Margin | ||||||||||||
Operating Taxes | ||||||||||||
Tax Rate | ||||||||||||
NOPAT | ||||||||||||
Net income | ||||||||||||
Dividends | ||||||||||||
Dividend yield | ||||||||||||
Proceeds from repurchase of equity | ||||||||||||
BB yield | ||||||||||||
| Debt | ||||||||||||
Debt current | ||||||||||||
Long-term debt | ||||||||||||
Deferred revenue | ||||||||||||
Other long-term liabilities | ||||||||||||
Net debt | ||||||||||||
| Cash flow | ||||||||||||
Cash from operating activities | ||||||||||||
CAPEX | ||||||||||||
Cash from investing activities | ||||||||||||
Cash from financing activities | ||||||||||||
FCF | ||||||||||||
| Balance | ||||||||||||
Cash | ||||||||||||
Long term investments | ||||||||||||
Excess cash | ||||||||||||
Stockholders' equity | ||||||||||||
Invested Capital | ||||||||||||
ROIC | ||||||||||||
ROCE | ||||||||||||
| EV | ||||||||||||
Common stock shares outstanding | ||||||||||||
Price | ||||||||||||
Market cap | ||||||||||||
EV | ||||||||||||
EBITDA | ||||||||||||
EV/EBITDA | ||||||||||||
Interest | ||||||||||||
Interest/NOPBT | ||||||||||||